Allianz Asset Management
TSHA icon

Allianz Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Allianz Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Hold
42,400
– – ﹤0.01% 2052
2026
Q1 		$190K Hold
42,400
– – ﹤0.01% 1942
2025
Q4 		$233K Buy
+42,400
New +$206K ﹤0.01% 1922

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allianz Asset Management's TSHA Position: Q2 2026 in Review

Allianz Asset Management held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 42,400 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #2052.

Allianz Asset Management first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Allianz Asset Management held 42,400 shares of Taysha Gene Therapies worth $289K as of Q2 2026.
  • Allianz Asset Management left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2052 holding.
  • Allianz Asset Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.